Follow Us:
Feb 20, 2019
ARKAY Therapeutics Announced as a Finalist in Most Successful Early Phase Research in 2019 Clinical & Research Excellence Awards
June 5, 2018
The U.S. FDA Approves ARKAY Therapeutics’ IND Application for Evaluating RK-01, a First-in-Class ‘Beta-cell-centric’ Drug Combination Product in Type 2 Diabetes Patients
Apr 11, 2018
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in-Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes
Oct 2, 2017
ARKAY Therapeutics Announces Notice Of Allowance Of Patent Application For First-In-Class “Beta-Cell-Centric” Drug, RK-01 For Type 2 Diabetes From The United States Patent Office
